ClinicalTrials.gg
Not yet recruitingNCT07165171GlyCoSupUpdated Sep 10, 2025

Periodontal Follow-up and Glycemy in Patients With Type 2 Diabetes

An interventional study of Innovative periodontal monitoring (SuP innovative) in Periodontal Disease, sponsored by Hospices Civils de Lyon. Not yet recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
516
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Periodontal Diseases with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Periodontal Diseases · France.

Planned enrollment
Largest of 13
516 · median 50
Started
2025
with 3 others
No phase
13 of 21
5 open now
Registered
19th of 21
by date
Lead sponsor
3 of 21
Hospices Civils de Lyon

Among the 21 studies in Periodontal Diseases with a site in France, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, and was the 19th registered.

Periodontal Diseases

871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.

Browse Periodontal Diseases studies →

Open to participants now

6 of the 21 studies in Periodontal Diseases with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Periodontal Diseases with a site in France, or all of them as a file.
02

Study summary

Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body.

Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local production of inflammatory mediators (IL6, TNF-alpha, etc.) and contributes to the increase in the systemic inflammatory load with increased levels of C-reactive protein.

Periodontitis is frequently found in diabetic patients; it is considered a complication of diabetes. Poor glycemic control in diabetes is associated with poor periodontal health, while periodontal infection is associated with dysglycemia and increased insulin resistance.

Periodontal treatment has been shown to reduce HbA1C levels and thus the risk of complications in diabetic patients.

The main objective is to evaluate the impact of innovative periodontal monitoring (with reminder systems and reinforcement of advice by SMS) versus standard periodontal monitoring on the glycemic control of diabetic patients treated for periodontitis, 2 years after the start of periodontal monitoring.

Read the detailed description

Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body.

Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local production of inflammatory mediators (IL6, TNF-alpha, etc.) and contributes to the increase in the systemic inflammatory load with increased levels of C-reactive protein.

Periodontitis is frequently found in diabetic patients; it is considered a complication of diabetes. Poor glycemic control in diabetes is associated with poor periodontal health, while periodontal infection is associated with dysglycemia and increased insulin resistance.

Periodontal treatment has been shown to reduce HbA1C levels and thus the risk of complications in diabetic patients.

However, periodontitis is a recurring disease; The implementation of periodontal monitoring (SuP) is essential throughout life after periodontal treatment, in order to prevent relapses. This monitoring, which must be carried out for life, includes the reassessment of periodontal criteria, professional instrumentation and oral hygiene (HBD) advice.

Visits every 3 months are generally recommended at the beginning, in order to regularly reinforce HBD advice. However, adherence to the SuP is difficult to obtain in the long term. In orthodontic patients, the use of reminder systems (SMS, emails, mobile applications, etc.) has a positive effect on HBD and periodontal criteria and would improve the rate of attendance at appointments in the medium term (3-12 months). A reminder and reinforcement system for HBD advice could therefore be integrated into the SuP in order to improve HBD and longer-term adherence in diabetic patients.

The main objective is to evaluate the impact of innovative periodontal monitoring (with reminder systems and reinforcement of advice by SMS) versus standard periodontal monitoring on the glycemic control of diabetic patients treated for periodontitis, 2 years after the start of periodontal monitoring.

This is a comparative experimental study to evaluate the effectiveness of a new monitoring strategy for type 2 diabetic patients who have been treated for periodontitis, a randomized controlled trial including an implementation study using a mixed methods approach (quantitative and qualitative).

The research will take place in 7 hospitals (Lille, Lyon, Nantes, Paris, Rennes, Strasbourg, Toulouse) and 7 privates dental centers in France.

Two types of care are proposed after periodontal treatment (all patients included will have previously benefited from standard periodontal treatment in the different centers).

The two groups compared will be:

  • For the Experimental Group: Innovative periodontal monitoring.
  • For the Control Group: Standard periodontal follow-up.

The primary endpoint is the HbA1c level (expressed in %) at 2 years after the date of randomization. The HbA1c level at 2 years will be collected by performing a routine dosage, in the patient's usual laboratory.

The target population of the GlyCoSuP project concerns adults with type 2 diabetes who have been treated for periodontitis.

After increasing by 10% to take into account those lost to follow-up, the total number of patients to be included will be 516 (258 patients per arm).

The duration of the inclusion period will be 24 months and the participation for each subject will be 24 months. In total, the total duration of the study will be 48 months.

03

Conditions studied

  • Periodontal Disease

Keywords

  • periodontal disease
  • Glycemy
  • Diabetes type 2
  • Follow-up
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -- Adult aged 18 years or older;
  • Presenting with type 2 diabetes (under ALD), balanced or not, for 6 months or more;
  • Having been treated in the previous 6 months for periodontitis (stages 1 to 4 according to the new classification of periodontal and peri-implant diseases EFP-AAP 2018) in one of the participating centers and presenting a clinical situation allowing the transition to the periodontal follow-up phase (; (absence or limited number of sites presenting clinical signs of persistent periodontal inflammation)
  • Presenting more than 6 teeth;
  • Possessing a smartphone or tablet with internet access;
  • Affiliated to social security;
  • Patient able to read, write and understand French
  • Having signed a consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patient presenting uncontrolled systemic diseases and diagnosed for less than 6 months or presenting a major aggravation of a systemic pathology according to the judgment of the investigator.
  • Pregnant or breastfeeding women;
  • Persons deprived of liberty by a judicial or administrative decision;
  • Adults subject to a legal protection measure (guardianship, curatorship).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
516 participants (estimated)

Study arms

  • Experimental
    Intervention group: SuP innovant (sending Short Message Service - SMS)

    For the Experimental Group: Innovative periodontal monitoring (SuP), consisting of: * visits every 3 months during 24 months with reinforcement of HBD advice and professional instrumentation - supra- and subgingival debridement if necessary. (common to the control group) * sending of different types of SMS: different types of SMS messages will be sent alternately. The SMS messages are intended for patients in the experimental group. The proposed approach aims to maintain contact with the patient at home and strengthen their commitment to a good oral hygiene routine over the long term. Text messages will be sent via the French CURECALL platform. The various text messages will be scheduled from the beginning of the periodontal follow-up.

    Procedure: Innovative periodontal monitoring (SuP innovative)

  • No intervention
    Control group: SuP standard

    For the Control Group: Standard periodontal follow-up (SuP), consisting of: visits every 3 months with reinforcement of HBD advice and professional instrumentation - supra- and subgingival debridement if necessary (common to the experimental group).

Interventions

  • ProcedureInnovative periodontal monitoring (SuP innovative)

    Different types of SMS messages will be sent alternately. * Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients. * Type 2 SMS: Interactive SMS text messages written in the form of questions. * Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment. The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient: * 1 Type 1 SMS/week (medical advice or information); * 1 Type 2 SMS/month (interactive with suggested answers); * 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up.

    Also known as: Innovative periodontal monitoring (SuP innovative

06

What researchers measure

Primary outcomes

  1. HbA1c level (expressed as a %)

    The HbA1c level will be collected by routine testing in the patient's usual laboratory. This endpoint will be collected without knowing the patient's group. To limit missing data, a letter will be sent to the healthcare professional responsible for the patient's diabetes management (of the two groups) at the time of inclusion. If necessary, their physician may be contacted to retrieve this data, with the patient's consent. During the previous visit, the patient will be reminded to bring their test results for the next visit. This will also be noted in the appointment reminder text message.

    Time frame: At 2 years after the date of randomization.

Secondary outcomes

  1. Periodontal criteria: - average probing depth (mm),

    The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices. Collected by the investigator at inclusion and then every 3 months up to 24 months post-randomization.

    Time frame: At inclusion and then every 3 months up to 24 months post-randomization.

  2. Periodontal criteria: - bleeding index on probing (%),

    The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.

    Time frame: At inclusion then every 3 months until up to 24 months post-randomization.

  3. Periodontal criteria: - average clinical attachment level (mm),

    The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.

    Time frame: At inclusion and then every 3 months up to 24 months post-randomization.

  4. Periodontal criteria: - number of sites with a probing depth strictly greater than or equal to 4 mm (but with bleeding on probing),

    The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.

    Time frame: at inclusion and then every 3 months up to 24 months post-randomization.

  5. Periodontal criteria: - number of tooth loss,

    The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.

    Time frame: at inclusion and then every 3 months up to 24 months post-randomization.

  6. Periodontal criteria: - number of sites re-instrumented by debridement/root planing

    The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.

    Time frame: at inclusion and then every 3 months up to 24 months post-randomization.

  7. Diabetic Pathology Criteria: - HbA1c level (%),

    HbA1c level (%): data collected from routine laboratory tests performed as part of diabetes management, in accordance with the recommendations of the French National Authority for Health (HAS), As a last resort, the physician may be contacted with the patient's consent to ensure that there have been no changes to the prescription since the last visit.

    Time frame: At inclusion then every 3 months until 24 months post-randomization.

07

Study locations

8 sites
  • Hôpital Charles Foix
    Ivry-sur-Seine, 94200, France
    • Marjolaine GOSSET, Pr · Contactmarjolaine.gosset@aphp.fr · 1 49 59 48 03
    • Marjolaine GOSSET, Pr · Principal investigator
  • Centre Hospitalo-Universitaire de Lille
    Lille, 59000, France
  • Hospices Civils de Lyon, Centre de Soins Dentaires.
    Lyon, 69007, France
  • Centre Hospitalo-Universitaire de Nantes
    Nantes, 44000, France
    • Xavier STRUILLOU, MD · Contact6 61 37 46 16
    • Xavier STRUILLOU, MD · Principal investigator
  • Centre Hospitalo-Universitaire de Rennes
    Rennes, 35000, France
  • Cabinet libéral
    Saint-Victor-de-Cessieu, 38110, France
  • Hôpitaux universitaires de Strasbourg
    Strasbourg, 67000, France
    • Olivier HUCK, Pr · Contacto.huck@unistra.fr · 3 88 11 69 47
    • Olivier HUCK, MD · Principal investigator
  • Centre Hospitalo-Universitaire de Toulouse
    Toulouse, 31300, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2029, 48 months later.

Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 48 months is above that.

Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Sep 10, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Oct 1, 2029
CompletionEst.
Oct 1, 2030
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07165171
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Sep 10, 2025

Study contacts

Kerstin GRITSCH, Prefessor
Contact
kerstin.gritsch@chu-lyon.fr
4 27 85 40 30 ext. +33
Julie HAESEBAERT, Professor
Contact
julie.haesebaert01@chu-lyon.fr
472115165 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion